Carotid
free-floating thrombus (CFFT) is uncommon [1]. This entity was discovered and
described in 1966 by Ehrenfeld. Its occurring in 0,4% of cases in non-Covid-19
patients [2]. Since the emergence of the COVID-19 infection, we are describing
the case N-16 of a free-floating clot in the carotid artery complicating
SARS-Cov 2 infection. In our knowledge, this is the first described case in
TUNISIA. CFFT is defined as a blood clot attached to the arterial wall with
blood flow in distality [3]. The main etiology of this state, is migration or
rupture of an atherosclerotic plaque. Other etiologies are rare including
arterial dissection, aneurysm, prothrombotic factors such as inflammatory and
infectious diseases [4]. The internal carotid artery is commonly the most
affected with an estimated frequency of 7% [5]. It’s now known that Covid-19
infection is related to an hyperinflammation state. Indeed, higher levels of
WBC count and neutrophil-to-lymphocyte ratio with important rates of CRP and
CPK levels were found in Sars cov-2 patients compared to other patients. This
hyperinflammation can be explained by an abnormal circulating immune complex
formation in response to COVID-19 infection [6]. This Inflammation state
associated with the platelets activation due to infection are probably involved
in the pathogenesis of hypercoagulability leading to thrombi formation.
Furthermore, disseminated intravascular coagulation is more frequent in
Covid-19 patients with a rate of 8,7% [7]. Other hypothesis suggested that there
is an endothelial dysfunction caused by invasion of endothelial cells by the
virus [8]. This hypercoagulability leads to a higher prothrombotic state in
Sars-cov 2 patients explaining the increasing frequency of vessel occlusions
even without atherosclerotic disease.
In
literature, the COVID-19 patients with artery thrombosis characteristics are
male gender, obesity and less cardiovascular factors compared to other patients
[9]. In most cases, CFFT is symptomatic with a history of ischemic stroke [10].
The rate of stroke in Covid-19 patients is about 1% [11]. The feature of this
type of thrombus lies in its extreme fragility leading to recurrent cerebral
embolism. CT angiography is the gold standard in the diagnosis of CFFT finding
a specific sign called the donut sign [12]. The treatment is either a surgical
management or optimal medical strategy. Hosseini et al. reported a complete
resolution of the clot three months after the initiation of the anticoagulation
therapy [13]. In a study published in 2013, 24 patients were included with the
diagnosis of intraluminal carotid thrombus [14]. All of them had an
anticoagulation therapy first, ten of them had a delayed revascularization. The
results reported of all patients with the anticoagulation therapy in primary
intention were excellent with no ischemic nor hemorrhagic stroke. When
endarterectomy is indicated, the surgery should be done a maximum of two weeks
after the patients last symptoms [15]. Endovascular approach can also be
considered in CFFT with stenting, aspiration or reversal of flow [10]. The
major problem of arterial thrombosis in Covid-19 patients remains the risk of
re-thrombosis despite anticoagulation. In fact, cases of recurrence have been
reported in literature and even in our daily practice, patients who underwent
surgical management for artery thrombosis and then have had an anticoagulation,
presented a re-thrombosis.